NewAmsterdam Pharma Company NV [NAMS] stock is trading at $33.94, up 4.72%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NAMS shares have gain 6.53% over the last week, with a monthly amount glided 0.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on August 25, 2025, and set its price target to $45. On July 17, 2025, Goldman initiated with a Neutral rating and assigned a price target of $27 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $42 on June 17, 2025. Stifel initiated its recommendation with a Buy and recommended $44 as its price target on June 10, 2025. Cantor Fitzgerald started tracking with a Overweight rating for this stock on June 04, 2025, and assigned it a price target of $42. In a note dated December 30, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $48 on this stock.
NewAmsterdam Pharma Company NV [NAMS] stock has fluctuated between $14.06 and $42.00 over the past year. Currently, Wall Street analysts expect the stock to reach $47.2 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $33.94 at the most recent close of the market. An investor can expect a potential return of 39.07% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
NewAmsterdam Pharma Company NV [NASDAQ:NAMS] reported sales of 35.24M for the trailing twelve months, which represents a drop of -98.80%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -5.76%, Pretax Profit Margin comes in at -6.27%, and Net Profit Margin reading is -6.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.29 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, NewAmsterdam Pharma Company NV’s Current Ratio is 12.57. Also, the Quick Ratio is 12.57, while the Cash Ratio stands at 9.24. Considering the valuation of this stock, the price to sales ratio is 109.21, the price to book ratio is 5.28.
Transactions by insiders
Recent insider trading involved Mayur Somaiya, Affiliate, that happened on Jan 20 ’26 when 0.2 million shares were purchased. Chief Scientific Officer, Kastelein Johannes Jacob Piete completed a deal on Jan 05 ’26 to sell 6000.0 shares. Meanwhile, Chief Accounting Officer Kooij Louise Frederika sold 2647.0 shares on Jan 05 ’26.
